AR036501A1 - Metodo para la sintesis de hexahidro-furo[2,3-b]furan-3-ol, e intermediarios - Google Patents

Metodo para la sintesis de hexahidro-furo[2,3-b]furan-3-ol, e intermediarios

Info

Publication number
AR036501A1
AR036501A1 ARP020103403A ARP020103403A AR036501A1 AR 036501 A1 AR036501 A1 AR 036501A1 AR P020103403 A ARP020103403 A AR P020103403A AR P020103403 A ARP020103403 A AR P020103403A AR 036501 A1 AR036501 A1 AR 036501A1
Authority
AR
Argentina
Prior art keywords
formula
furo
furan
hexahydro
aralkyl
Prior art date
Application number
ARP020103403A
Other languages
English (en)
Original Assignee
Tibotec Pharm Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8180908&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR036501(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Tibotec Pharm Ltd filed Critical Tibotec Pharm Ltd
Publication of AR036501A1 publication Critical patent/AR036501A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D307/18—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/20—Oxygen atoms
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Furan Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Método para la síntesis de hexahidro-furo[2,3-b]furan-3-ol de la fórmula (4) a partir de un intermediario de la fórmula (1) en la cual cada uno de P1 y P2 representa independientemente un hidrógeno, un grupo protector de hidroxi o juntos pueden formar un grupo protector de diol próximo, que comprende transformar dicho intermediario de la fórmula (1) en un derivado de nitrometano de la fórmula (2) en la cual R1 representa alquilo, arilo o aralquilo, R2 representa hidrógeno o C(=O)OR3, R3 representa un alquilo, arilo, aralquilo o R3, en caso de estar presente, y R1, junto con los átomos a los cuales están unidos, pueden formar un grupo cíclico de 6 a 8 miembros que puede estar optativamente sustituido con alquilo, aralquilo o arilo, seguidamente transformar dicho derivado de nitrometano en un derivado de tetrahidrofurano de la fórmula (3) en la cual OR4 representa un alcoholato, y luego transformar el intermediario de la fórmula (3) en hexahidro-furo[2,3-b]furan-3-ol de la fórmula (4) por medio de una reacción de ciclación intramolecular. El hexahidro-furo[2,3-b]furan-3-ol es una parte farmacológica importante presente en la estructura de los inhibidores de proteasa viral.
ARP020103403A 2001-09-10 2002-09-09 Metodo para la sintesis de hexahidro-furo[2,3-b]furan-3-ol, e intermediarios AR036501A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP01203416 2001-09-10

Publications (1)

Publication Number Publication Date
AR036501A1 true AR036501A1 (es) 2004-09-15

Family

ID=8180908

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP020103403A AR036501A1 (es) 2001-09-10 2002-09-09 Metodo para la sintesis de hexahidro-furo[2,3-b]furan-3-ol, e intermediarios

Country Status (28)

Country Link
US (1) US7126015B2 (es)
EP (1) EP1448567B1 (es)
JP (1) JP4521185B2 (es)
KR (1) KR100894673B1 (es)
CN (2) CN101172980B (es)
AP (1) AP1758A (es)
AR (1) AR036501A1 (es)
AT (1) ATE453648T1 (es)
AU (1) AU2002333809C1 (es)
BR (1) BRPI0212341B8 (es)
CA (1) CA2459168C (es)
CY (1) CY1109974T1 (es)
DE (1) DE60234952D1 (es)
DK (1) DK1448567T3 (es)
EA (1) EA010883B1 (es)
ES (1) ES2338538T3 (es)
HK (1) HK1068887A1 (es)
HR (1) HRP20040320B1 (es)
HU (1) HU229505B1 (es)
IL (2) IL160166A0 (es)
MX (1) MXPA04002247A (es)
NO (1) NO328934B1 (es)
NZ (1) NZ531641A (es)
PL (1) PL224030B1 (es)
PT (1) PT1448567E (es)
SI (1) SI21463B (es)
WO (1) WO2003022853A1 (es)
ZA (1) ZA200401501B (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003247651A1 (en) * 2002-06-27 2004-01-19 Smithkline Beecham Corporation PREPARATION OF STEREOISOMERS OF (3ALPHA, 3ALPHA/BETA, 6ALPHA/BETA) HEXAHYDROFURO(2,3-b)FURAN-3-OL
WO2004060895A1 (ja) * 2002-12-27 2004-07-22 Sumitomo Chemical Company, Limited ヘキサヒドロフロフラノール誘導体の製造方法、その中間体及びその製造方法
UA85567C2 (en) 2003-12-23 2009-02-10 Тиботек Фармасьютикелз Лтд. Process for the preparation of (3r,3as,6ar)-hexahydrofuro [2,3-b] furan-3-yl (1s,2r)-3-[[(4-aminophenyl) sulfonyl] (isobutyl) amino]-1-benzyl-2-hydroxypropylcarbamate
TWI383975B (zh) * 2004-03-31 2013-02-01 Tibotec Pharm Ltd 製備（３Ｒ，３ａＳ，６ａＲ）六氫-呋喃并〔２，３-ｂ〕呋喃-３-醇之方法
JP5549898B2 (ja) * 2006-03-31 2014-07-16 独立行政法人産業技術総合研究所 ５−ヒドロキシメチル−２−フルフラールの製造法
DK2089371T3 (da) * 2006-11-09 2011-05-16 Tibotec Pharm Ltd Fremstillingsmåde til fremstilling af hexahydrofuro[2,3-b]furan-3-OL
CN101024646B (zh) * 2007-02-06 2010-07-14 启东东岳药业有限公司 4-甲氧基呋喃并呋喃-2-酮的纯化方法
WO2008132154A1 (en) 2007-04-27 2008-11-06 Tibotec Pharmaceuticals Ltd. Methods for the preparation of n-isobutyl-n-(2-hydroxy-3-amino-4-phenylbutyl)-p-nitrobenzenesulfonylamide derivatives
US8592487B2 (en) 2007-10-26 2013-11-26 Concert Pharmaceuticals, Inc. Deuterated darunavir
TWI482775B (zh) 2008-09-01 2015-05-01 Tibotec Pharm Ltd 用於製備（３ｒ，３ａｓ，６ａｒ）－六氫呋喃并〔２，３－ｂ〕呋喃－３－基（１ｓ，２ｒ）－３－〔〔（４－胺基苯基）磺醯基〕（異丁基）胺基〕－１－苯甲基－２－羥基丙基胺基甲酸酯之方法
EP2358198A4 (en) * 2008-10-24 2012-11-14 Concert Pharmaceuticals Inc HYDROXYETHYLAMINO SULFONAMIDE DERIVATIVES
US8921415B2 (en) 2009-01-29 2014-12-30 Mapi Pharma Ltd. Polymorphs of darunavir
US9062065B2 (en) 2009-10-30 2015-06-23 Lupin Limited Process for preparation of darunavir and darunavir ethanolate of fine particle size
AU2011210349A1 (en) 2010-01-28 2012-07-05 Mapi Pharma Limited Process for the preparation of darunavir and darunavir intermediates
CA2818895C (en) 2010-11-23 2020-02-25 Matrix Laboratories Ltd Process for the preparation of (3r, 3as, 6ar)-hexahydrofuro [2,3-b] furan-3-ol
WO2012075122A2 (en) * 2010-11-30 2012-06-07 Purdue Research Foundation Processes and intermediates for preparing substituted hexahydrofuro [2,3-b] furans
EP2877474B1 (en) 2012-07-24 2020-11-04 Laurus Labs Limited A process for preparation of darunavir
JPWO2014024898A1 (ja) * 2012-08-09 2016-07-25 住友化学株式会社 ヘキサヒドロフロフラノール誘導体の製造方法
CN103864813B (zh) * 2012-12-18 2017-02-22 上海迪赛诺化学制药有限公司 一种合成六氢呋喃并[2,3‑b]呋喃‑3‑醇及其对映体的方法
EP3313847A4 (en) * 2015-06-25 2019-04-24 MSN Laboratories Private Limited PROCESS FOR PREPARING (3R, 3AS, 6AR) HEXAHYDROFURO [2,3-B] FURAN-3-YL ESTER OF [(1S, 2R) -3 - [[(4-AMINOPHENYL) SULFONYL] (2-METHYLPROPYL) ACID ) AMINO] -2-HYDROXY-1- (PHENYLMETHYL) PROPYL] -CARBAMIC AND ITS AMORPHOUS FORM
WO2017041228A1 (zh) * 2015-09-08 2017-03-16 浙江九洲药业股份有限公司 六氢呋喃并呋喃醇衍生物的制备方法、其中间体及其制备方法
CN110423228B (zh) * 2016-02-05 2023-01-10 成都博腾药业有限公司 一种制备地瑞那韦中间体的方法
ES2881949T3 (es) 2016-10-27 2021-11-30 Gilead Sciences Inc Forma cristalina de base libre de darunavir
CN106928248B (zh) * 2017-02-04 2019-01-04 青岛科技大学 一种制备(3R,3aS,6aR)六氢呋喃并[2,3-b]呋喃-3-醇的方法
CN116103348A (zh) 2018-03-16 2023-05-12 江苏瑞科医药科技有限公司 六氢呋喃并呋喃醇衍生物的制备方法、其中间体及其制备方法
CN114853774A (zh) * 2022-06-24 2022-08-05 盐城迪赛诺制药有限公司 一种达卢那韦关键中间体的制备方法
CN115557964A (zh) * 2022-10-18 2023-01-03 启东东岳药业有限公司 一种药物化合物的制备方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU35543A1 (es) * 1980-10-09 1983-05-05 Hoffmann La Roche Prostaglandines
NZ224497A (en) * 1987-05-18 1990-04-26 Janssen Pharmaceutica Nv Pharmaceutical composition comprising flunarizine
US5281420A (en) * 1992-05-19 1994-01-25 The Procter & Gamble Company Solid dispersion compositions of tebufelone
AU6828894A (en) * 1993-05-14 1994-12-12 Merck & Co., Inc. Hiv protease inhibitors
DK0715618T3 (da) 1993-08-24 1999-08-23 Searle & Co Hydroxyethylaminosulfonamider til anvendelse som inhibitorer af retrovirale proteaser
RU2089545C1 (ru) * 1994-09-28 1997-09-10 Ярославский государственный технический университет Способ получения 2-метил-2-этил-1,3-диоксолан-4-ил-метилметакрилата
DE19510566A1 (de) * 1995-03-23 1996-09-26 Kali Chemie Pharma Gmbh Benzazepin-, Benzoxazepin- und Benzothiazepin-N-essigsäurederivate sowie Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
DE19638020A1 (de) * 1996-09-18 1998-03-19 Solvay Pharm Gmbh Die gastrointestinale Durchblutung fördernde Arzneimittel
KR20040004416A (ko) * 1997-01-30 2004-01-13 노파르티스 아게 오일을 함유하지 않은 사이클로스포린 ａ 함유 제약 조성물
AU771780B2 (en) * 1998-06-23 2004-04-01 Board Of Trustees Of The University Of Illinois, The Fitness assay and associated methods
WO1999067254A2 (en) * 1998-06-23 1999-12-29 The United States Of America Represented By The Secretary, Department Of Health And Human Services Multi-drug resistant retroviral protease inhibitors and use thereof
KR100336090B1 (ko) * 1998-06-27 2002-05-27 윤승원 오일, 지방산 또는 이들의 혼합물을 함유한 난용성 약물의 고형분산제제
DE19906310A1 (de) * 1999-02-16 2000-08-17 Solvay Pharm Gmbh Arzneimittel zur Behandlung von Bluthochdruck
DE19932555A1 (de) * 1999-07-13 2001-01-18 Solvay Pharm Gmbh Arzneimittel mit protektiver Wirkung gegen oxidativ-toxische und insbesondere gegen kardiotoxische Substanzen
DK1222192T3 (da) * 1999-10-06 2008-10-20 Tibotec Pharm Ltd Hexahydrofuro-2,3-b furan-3-yl-N-3-(1,3-benzodioxol-5-ylsulfonyl)(isobutyl)amino-1-benzyl-2-hydroxypropyl-carbamat som retroviral proteaseinhibitor

Also Published As

Publication number Publication date
AP1758A (en) 2007-07-30
CY1109974T1 (el) 2014-09-10
EA010883B1 (ru) 2008-12-30
KR100894673B1 (ko) 2009-04-24
SI21463B (sl) 2011-08-31
AU2002333809B9 (en) 2008-06-26
IL160166A (en) 2012-05-31
PL367817A1 (en) 2005-03-07
EP1448567B1 (en) 2009-12-30
CN1553915A (zh) 2004-12-08
CA2459168C (en) 2014-01-28
PL224030B1 (pl) 2016-11-30
JP4521185B2 (ja) 2010-08-11
EA200400430A1 (ru) 2004-08-26
AU2002333809B8 (en) 2008-07-03
HUP0402140A2 (hu) 2005-02-28
BRPI0212341B8 (pt) 2021-05-25
HRP20040320A2 (en) 2005-04-30
AU2002333809C1 (en) 2009-02-05
HU229505B1 (hu) 2014-01-28
SI21463A (sl) 2004-10-31
ZA200401501B (en) 2005-07-27
NO328934B1 (no) 2010-06-21
EP1448567A1 (en) 2004-08-25
DK1448567T3 (da) 2010-04-26
NZ531641A (en) 2005-08-26
HK1068887A1 (en) 2005-05-06
KR20040029425A (ko) 2004-04-06
CA2459168A1 (en) 2003-03-20
NO20041434L (no) 2004-06-10
PT1448567E (pt) 2010-03-12
JP2005502707A (ja) 2005-01-27
US20040249175A1 (en) 2004-12-09
AU2002333809B2 (en) 2008-02-28
ATE453648T1 (de) 2010-01-15
BRPI0212341B1 (pt) 2019-04-02
CN101172980B (zh) 2011-11-16
AP2004002981A0 (en) 2004-03-31
US7126015B2 (en) 2006-10-24
IL160166A0 (en) 2004-07-25
BR0212341A (pt) 2004-07-27
HUP0402140A3 (en) 2007-05-29
MXPA04002247A (es) 2005-09-07
WO2003022853A1 (en) 2003-03-20
HRP20040320B1 (hr) 2012-11-30
CN100519561C (zh) 2009-07-29
DE60234952D1 (de) 2010-02-11
ES2338538T3 (es) 2010-05-10
CN101172980A (zh) 2008-05-07

Similar Documents

Publication Publication Date Title
AR036501A1 (es) Metodo para la sintesis de hexahidro-furo[2,3-b]furan-3-ol, e intermediarios
AR069435A1 (es) Derivados de aminotiazol, proceso para la obtencion de los mismos, composiciones farmaceuticas y su uso como inhibidores de la fbpasa
AR081577A1 (es) Derivados de aminopirimidina como moduladores de la lrrk2
ECSP10010019A (es) Proceso para la producir derivados de piripiropeno e intermediarios para la producción de los mismos
AR045386A1 (es) [1,8] naftiridin-2-onas y compuestos relacionados para el tratamiento de la esquizofrenia
AR057023A1 (es) Compuestos heterociclicos con propiedades inhibidoras de hiv-integrasa
CO6150140A2 (es) Inhibidores de proteina tirosina fosfatasa humana y metodos de uso
AR018634A1 (es) Derivados de benzo(b)tiepin-1,1,-dioxido, procedimiento para su preparacion, medicamentos conteniendo estos compuestos, procedimiento para la preparacion de medicamentos y su empleo para la preparacion de medicamentos.
AR036093A1 (es) Compuestos derivados de tiazolidinilo, pirrolidinilo, oxazolidinilo, piperidilo, morfolinilo y tiomorfolinilo, su uso, composiciones farmaceuticas que los comprenden, y compuestos intermediarios
ECSP066667A (es) Derivados de ciclohexano espirociclicos
CO5580746A2 (es) Derivados de fenil-piperazina como inhibidores de la reabsorcion de la serotonina
CO5690640A2 (es) Derivados espirociclicos heterociclicos y procedimientos para su uso
CO5690593A2 (es) Nuevos derivados de pirimidin 2-amina
CO4950519A1 (es) Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion
AR063142A1 (es) Derivados de 2-(bencimidazolil) purina y purinonas 6-sustituidas utiles como inmunosupresores,y composiciones farmaceuticas que los contienen.
EA200970493A1 (ru) Макроциклические ингибиторы вируса гепатита с
ES2530943T3 (es) Derivados de la cromenona con actividad antitumoral
AR067613A1 (es) Inhibidores de adn-pk, uso y sintesis de los mismos
AR079553A1 (es) Derivados de diaza-espiro-[5,5]-undecanos, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de trastornos del snc, tales como trastornos del sueno y de la dependencia,entre otros.
CO5580815A2 (es) Derivados de adamantana, procesos para su preparacion y composiciones farmaceuticas que los contienen
CO6420344A2 (es) Derivados de triazolopiridina como inhibidores de proteínas cinasas activadas por mitogeno p38 (map)
AR075207A1 (es) Derivados de 4-amino-7,8-dihidropirido (4,3-d) pirimidin-5-(6h) - ona
CO5601021A2 (es) Derivados de quinazolinona, composiciones farmaceuticas que los contienen y su proceso de preparacion y su uso como antagonistas cb
AR042067A1 (es) Derivados de anilinopirazol utiles en el tratamiento de la diabetes
AR052871A1 (es) Una sintesis exo-selectiva de analogos de himbacina

Legal Events

Date Code Title Description
FG Grant, registration